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Abstract
Background: Cannabis intoxication is related to a number of physical and mental health risks with ensuing social
costs. However, little attention has been given to the investigation of possible pharmacological interactions in this
condition.
Objective: To review the available scientific literature concerning pharmacological interventions for the treatment
of the acute effects of cannabis.
Methods: A search was performed on the Pubmed, Lilacs, and Scielo online databases by combining the terms
cannabis, intoxication, psychosis, anxiety, and treatment. The articles selected from this search had their reference
lists checked for additional publications related to the topic of the review.
Results: The reviewed articles consisted of case reports and controlled clinical trials and are presented according
to interventions targeting the physiological, psychiatric, and cognitive symptoms provoked by cannabis. The
pharmacological interventions reported in these studies include: beta-blockers, antiarrhythmic agents, antagonists
of CB-1 and GABA-benzodiazepine receptors, antipsychotics, and cannabidiol.
Conclusion: Although scarce, the evidence on pharmacological interventions for the management of cannabis
intoxication suggests that propanolol and rimonabant are the most effective compounds currently available to
treat the physiological and subjective effects of the drug. Further studies are necessary to establish the real
effectiveness of these two medications, as well as the effectiveness of other candidate compounds to counteract
the effects of cannabis intoxication, such as cannabidiol and flumazenil.
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Introduction
Cannabis sativa has Δ
9-tetrahydrocannabinol (Δ
9-THC),
isolated in the 1960s [1], as its main psychoactive com-
pound. The concentration of Δ
9-THC in the different
presentations of cannabis (marijuana, hashish, skunk) is
proportional to the intensity of its toxic effects. In can-
nabis, considered to be the most consumed illicit sub-
stance in the world [2], increased concentrations of Δ
9-
THC have been reported in recent years [3-5].
At the same time, there has been an increase in the
number of patients reporting to specialized services with
complaints related to the use of cannabis. A survey in
the USA revealed that between 1992 and 1998 the
demand for treatment at specialized services has
doubled, with the percentage of admissions for the treat-
ment of cannabis-related disorders (23%) approaching
the admission rates relative to cocaine (27%) and her-
oine (23%), considering all drug-related hospitalizations
[6].
The use of cannabis has been associated with several
psychological, behavioral, and social problems [2].
Besides the chronic effects of the continued use of can-
nabis, such as dependence, abstinence, varying degrees
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tory disorders, its acute effects have also been related to
significant physical and mental health problems [7,8],
and an increasing number of emergency admissions has
been linked to cannabis use [9,10].
The intoxication by cannabis is associated with subjec-
tive symptoms of euphoria, perceptual distortion, con-
tinuous giggling, sedation, lethargy, impaired perception
of time, difficulties in the performance of complex men-
tal processes, impaired judgment and social withdrawal
[11]. In addition, physical signs of conjunctival hypere-
mia, increased appetite, dry mouth, and tachycardia can
develop in the period of approximately two hours after
the use of the substance [11], corresponding to the plas-
matic peak of Δ
9-THC.
In general, the acute toxicity of cannabinoids is con-
sidered to be low. Nevertheless, there are reports of
death by brain infarction - especially among teenagers -
following the acute use of marijuana [12,13] as well as
of cases of patients with severe sequelae resulting from
this complication [14]. Similarly, there are reports of
coma in children induced by the accidental intake of
cannabis [15], in addition to cases of cardiac arrhythmia
[16-20], acute myocardial infarction [21], and transitory
ischemic attacks [14]. Factors such as increased heart
effort, elevated levels of catecholamine and carboxyhe-
moglobin in the blood, as well as the occurrence of pos-
tural hypotension are among the most commonly
reported factors of cardiovascular disease associated
with intoxication by cannabis [22].
It is known that cannabis intoxication leads to
impaired motor ability, attention, and short-term mem-
ory [8,23]. In accordance with this, many studies have
found a higher prevalence of cannabis use among dri-
vers involved in accidents than in the general population
[8].
Currently, there is consistent evidence that people
who use cannabis on a regular basis have a higher pro-
portion of acute psychiatric disorders, aggravated by
other factors such as personality traits, pre-existing vul-
nerability, and substance use at an early age [24]. First-
time use and the dose of cannabis are among the main
factors related to this occurrence [23].
Panic and anxiety attacks are among the most com-
monly reported psychiatric symptoms related to canna-
bis intoxication and are often responsible for the
discontinuation of the use of the substance [23]. Acute
psychotic episodes related to cannabis intoxication are
described in terms of confusion, disorientation, amnesia,
depersonalization, delusions, hallucinations, paranoid
ideation, psychomotor agitation, labile affect, and hosti-
lity [25]. These symptoms are usually gone after a maxi-
mum of one week abstinence [26]. In some cases,
psychotic episodes secondary to the use of cannabis can
persist for a substantial period of time after the acute
intoxication and may have some of the features of acute
schizophreniform disorders [24,27,28]. Further evidence
is provided by a systematic review on longitudinal and
population-based studies, which showed that cannabis
use significantly increases the risk of developing psycho-
tic illnesses in a dose-dependent manner [29].
There is strong evidence that cannabis use can have
major detrimental effects on the course of the illness
when patients with a pre-existing psychotic condition
continue to use the drug [30]. In addition to worsening
the outcome and exacerbating the symptoms, cannabis
use by people with psychosis can lead to sudden beha-
vioral disturbances such as increased proneness to vio-
lence, criminal activity, suspiciousness, and
hallucinations [31].
Lately, attempts have been made to better understand
the neurobiological mechanisms underlying cannabis-
related disorders and the functioning of the endogenous
cannabinoid system. There is increasing interest for the
development of medications capable to reduce the mor-
bidity of these disorders. Because marijuana intoxication
is a major public health problem with a growing
demand for assistance at emergency departments, the
study of possible pharmacological interventions that
might help in the management of the acute effects of
cannabis use is of great clinical and social relevance.
Method
This study is a bibliographic review on pharmacological
interventions for the treatment of the acute effects of
cannabis. The search for articles was performed on the
PubMed, LILACS,a n dSciELO online databases using
the search terms cannabis, intoxication, psychosis, anxi-
ety,a n dtreatment, and yielded a total of 174 matches.
Additionally, an active search was conducted for related
articles in the reference lists of the selected publications,
which included case reports, controlled clinical trials,
clinical trials of psychiatric and non-psychiatric medica-
tions, trials that promoted symptom reduction (physical,
psychological or cognitive), and investigations related to
the period of cannabis intoxication. Inclusion criteria
were articles published in English, Spanish or Portu-
guese, no time limit up to October of 2011. Only those
studies involving human samples were included. Taken
together, the database and the hand search provided ten
articles considered relevant for this review.
The results were subdivided according to interventions
targetting the physiological and psychological acute
effects of cannabis.
Results
The analysis of research reports of pharmacological
interventions against cannabis-related problems showed
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subject. Ten studies that fulfilled the inclusion criteria
consisted of case reports and controlled clinical trials.
Physiological effects
Cardiovascular effects, such as palpitations, are among
the best known clinical findings in cannabis intoxication.
These symptoms have been suggested to occur as a
result of the response induced by catecholamines,
released by the action of the drug in the peripheral
autonomic system [32]. The use of propranolol in the
control of these effects, proposed by Beaconsfield et al.
(1972) [33], was assessed in a placebo-controlled trial.
Sulkowski et al. (1977) [34] observed that the use of this
medication one hour prior to the use of marijuana sig-
nificantly attenuated the occurrence of tachycardia, as
well as the increase in blood pressure and conjunctival
hyperemia in six healthy experienced marijuana
smokers.
In two studies conducted by Huestis et al. (2001;
2007) [35,36], the compound rimonabant, previously
known as SR141716, was also associated with reduced
cannabis-induced tachycardia. This drug is an antagonist
of CB-1 cannabinoid receptors and presented its effects
at different doses (40 mg and 90 mg) administered two
hours before the use of marijuana.
The tachycardia reduction observed with the use of
propranolol and rimonabant was independent from
pharmacokinetic interactions, which suggests a specific
action of these compounds in the blockade of the acti-
vation of the sympathetic autonomic system related to
the use of cannabis [20]. Although the two drugs were
administered as a pretreatment in those studies, it is
possible that they could be used to control tachycardia
and high blood pressure in cannabis intoxication. Other
forms of cardiac arrhythmia have been associated with
the use of cannabis. The occurrence of arrhythmias
such as atrial fibrillation seems to be associated with
effects resulting from the parasympathetic stimulation
induced by cannabis and observed with the use of
higher doses [20]. In case reports describing the occur-
rence of atrial fibrillation associated with the use of can-
nabis, antiarrythmic agents like flecainide [20],
propafenone [18], and digoxin [16] were successfully
employed in the normalization of the cardiac rhythm.
According to Fisher et al. (2005) [20], the use of antiar-
rythmic agents would be efficient in patients with no
structural cardiac alterations.
T h eo c c u r r e n c eo fc o m a t o s es t a t e sd u et oc a n n a b i s
intoxication is very rare and, when it happens, it usually
is a result of accidental ingestion of the drug by chil-
dren. Flumazenil, an antagonist of the GABA-benzodia-
zepine receptor complex, is generally indicated for the
treatment of benzodiazepine intoxication and as a
therapeutic test in coma states of unknown origin.
Rubio et al. (1993) [16] described two cases of children
admitted at an emergency department in a comatose
state with a clinical history suggestive of intoxication
and positive laboratory tests for cannabis. Both patients
had a total recovery of the level of conscience after the
use of flumazenil.
Cannabis intoxication rarely leads to acute respiratory
deficiencies. Such deficiencies are more likely to develop
in cases of pre-existing pulmonary pathology or poly-
substance use. The appropriate therapeutic approach in
these cases requires aggressive measures that include
ventilatory support and the specific management of
alterations associated with metabolic acidosis, infections,
bronchospasm, and agitation. The occurrence of isolated
respiratory insufficiency caused by depression of the
central nervous system induced by cannabis is asso-
ciated with a better prognosis [37].
The cases of apnea and depression of the central ner-
vous system are potentially fatal and require ventilatory
assistance. Flumazenil was successfully used in the cases
reported by Rubio et al. (1993) [16], which support its
therapeutic use in cases of cannabis-induced coma. This
is consistent with other reports of reversal of the acute
brain effects of the drug in different conditions, such as
hepatic encephalopathy and intoxication by alcohol, car-
bamazepine, chloral hydrate, isoflurane, and antihista-
mines [38-40].
Psychiatric effects
The literature on the pharmacological management of
psychotic, anxious, and affective disorders related to
cannabis intoxication is limited. There is paucity of sub-
stance specific studies, since most are ‘substance use’
research without specifying the individual substance,
such as cannabis.
In the analysis of the pharmacological management of
acute psychotic states induced by cannabis, Berk et al.
(1999) [41] compared the effects of olanzapine and halo-
peridol. In this study, 30 patients who fulfilled the DSM-
IV criteria for cannabis-induced psychotic disorder were
randomly assigned to two groups divided according to
medication (10 mg/day each) administered for four
weeks. Both patient groups presented symptom reduc-
tion according to the psychiatric scales used (BPRS, CGI
severity and improvement), with no statistical differ-
ences between them. The use of haloperidol, as
expected, was associated with a greater occurrence of
extrapyramidal side-effects and the consequent use of
antiparkinsonian medication. According to some
authors, the use of typical antipsychotics could intensify
the use of substances, due mainly to the unpleasant
side-effects of this type of medication and competitive
metabolism with such substances [42]. Along these
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cial properties of atypical neuroleptics in schizophrenia
associated with substance abuse disorders [43]. Likewise,
as anticholinergic effects are among the symptoms of
cannabis intoxication, the use of antipsychotics without
such side-effects seems to be more appropriate.
Other pharmacological compounds have been tested
in the management of the acute subjective states
induced by cannabis. The use of rimonabant 90 mg/day
administered two hours before the use of marijuana
cigarettes promoted an average reduction of 75% in the
s i g n sa n ds y m p t o m so fc a n n a b i si n t o x i c a t i o nm e a s u r e d
one hour after use [36]. Subsequently, the same group
tested rimonabant in two distinct protocols, for the
same purpose: daily use for 15 days in the dose of 40
m g ,a n das i n g l ed o s eo f9 0m g .T h ed a i l ya d m i n i s t r a -
tion of the lower dose of rimonabant (40 mg) attenuated
the acute subjective effects after 8 but not 15 days of
use [35]. These findings concerning the use of rimona-
bant are relevant as they underscore the role of CB-1
receptors in the mediation of cannabis-induced psycho-
logical effects, consistent with previous reports from ani-
mal studies. Nonetheless, the lack of clinical trials with
the acute use of rimonabant and its important side-
effect of inducing depressive episodes [44] limit its
employment in this context.
The use of propranolol in the dose of 120 mg led to
the reduction of the subjective intoxication effects when
administered one hour after the use of marijuana cigar-
ettes and lends further support to the possibility -
poorly investigated to date - that the action of THC on
the brain could be partially mediated by beta-receptors.
Cannabidiol (CBD), a constituent of cannabis devoid
of the typical psychological effects induced by other
compounds of the plant, significantly attenuated the
anxious and psychotic symptoms induced by Δ
9-THC
(0, 5 mg/kg) in healthy volunteers when simultaneously
administered in the dose of 1 mg/kg [45]. The reduction
in the anxious and psychotic symptoms induced by
THC reported in this study opened novel perspectives
for its use in the management of psychotic and anxious
states, as attested by later studies performed by our
group [46-52]. However, the use of this cannabinoid in
the clinical practice is still in the experimental phase
and requires further investigation [53].
Cognitive effects
Only one study assessed the efficacy of pharmacological
interventions on the attenuation of the cognitive impair-
ment related to cannabis intoxication. Sulkowski et al.
(1977) [34], studying the effects of propranolol 120 mg
administered one hour after the use of a marijuana
cigarette with a controlled quantity of THC, reported no
changes in the performance of six volunteers submitted
to psychomotricity, attention, memory, and learning
tests. This finding, added to the impact of the laboral
and educational impairments associated with the use of
cannabis, highlights the importance of the search for
novel pharmacological interventions aimed at attenuat-
ing the cognitive impairment associated with intoxica-
tion by cannabis.
Conclusions
No publications were found related to the treatment of
panic attacks and manic and depressive syndromes spe-
cifically associated with cannabis intoxication. We pre-
dict that in emergency settings medications with acute
therapeutic effects for these conditions are used. Thus
benzodiazepines, such as lorazepam and alprazolam,
recommended for the acute management of panic disor-
der [54] can be used, but this requires research evidence
for further confirmation. Similarly, manic and depressive
syndromes, during the intoxication, can be managed by
means of medications (benzodiazepines and antipsycho-
tics) that attenuate important acute complaints like
insomnia, anxiety, psychomotor agitation, and suicidal
ideation. The use of antidepressants and mood stabili-
zers would be indicated only in the persistence of these
symptoms, with duration beyond the intoxication
period.
Cannabis intoxication is associated with significant
physical and mental health impairment with resulting
social costs; nonetheless, relatively few studies to date
were aimed at investigating the possible pharmacological
interventions in this condition [55]. However scarce, the
available evidence suggests that propranolol and rimona-
bant are valuable tools in the therapeutic arsenal for the
management of the physiological (especially cardiovas-
cular) and subjective intoxication effects of cannabis.
Flumazenil and cannabidiol were also found to counter-
act comatose and anxious and psychotic states, respec-
tively, although evidence in this regard still lacks
strength.
Our systematic searches revealed that articles on
intoxication by cannabis are scarce and report results
based on small samples. Future studies evaluating phar-
macological interventions directed at the attenuation of
the several acute effects induced by cannabis and at pro-
moting greater knowledge regarding its actions are
urgently necessary and opportune in the face of the
increasing challenge posed by such an important public
health problem.
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